OSR Holdings Inc Total Liabilities
OSR Holdings Inc total liabilities. Based on the latest financial reports, OSR Holdings Inc (OSRH) has total liabilities worth $41.71 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check OSRH cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of OSR Holdings Inc (2020–2025)
Total liabilities of OSR Holdings Inc from 2020 to 2025. This chart illustrates how OSR Holdings Inc's total liabilities have evolved over time, based on quarterly financial data. Explore OSRH strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
OSR Holdings Inc Competitors by Total Liabilities
The table below lists competitors of OSR Holdings Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lanakam S.A
AT:LANAC
|
Greece | €4.87 Million |
|
BHB Brauholding Bayern-Mitte AG
F:B9B
|
Germany | €6.53 Million |
|
TFP Solutions Bhd
KLSE:0145
|
Malaysia | RM6.57 Million |
|
Foresight Group Holdings Limited
LSE:FSG
|
UK | GBX79.08 Million |
|
Aurora Spine Corp
V:ASG
|
Canada | CA$6.11 Million |
|
MOSTOSTAL Płock SA
WAR:MSP
|
Poland | zł81.67 Million |
|
Xylo Technologies Ltd.
NASDAQ:XYLO
|
USA | $19.96 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down OSR Holdings Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OSRH total assets.
Liquidity & Leverage Metrics
OSR Holdings Inc Total Liabilities Ratios Explained
OSR Holdings Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OSR Holdings Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OSR Holdings Inc (2020–2025)
The table below shows the annual total liabilities of OSR Holdings Inc from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $44.20 Million | +402.92% |
| 2024-12-31 | $8.79 Million | -78.32% |
| 2023-12-31 | $40.53 Million | +235352.29% |
| 2022-12-31 | $17.22K | -97.57% |
| 2021-12-31 | $707.21K | +119.93% |
| 2020-12-31 | $321.56K | -- |
About OSR Holdings Inc
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tu… Read more